A. AHA occurs in 1 of every 5000 men B. AHA occurs commonly in pediatric patients C. 80% of patients with AHA are 65 years of age or older D. AHA occurs more frequently in women than in men

A. Autoantibodies to factor VIII B. Alloantibodies to factor VIII C. Autoantibodies to factor IXa D. Alloantibodies to factor IXa

A. Age less than 18 years B. More than 6 months postpartum C. Rheumatoid arthritis D. Pneumonia

A. Gastrointestinal tract B. Joints C. Mucous membranes D. Muscles

A. Autoantibody levels are low in patients with drug-induced AHA B. Bleeding symptoms are often non-life-threatening C. Morbidity is 20% or higher in patients aged 65 years and older D. Most patients with AHA die of causes other than AHA and bleeding

A. Replacement agent, such as recombinant porcine sequence factor VIII B-domain-deleted product B. Bypassing agent, such as activated prothrombin complex concentrate C. Hemostatic agent, such as desmopressin acetate D. Immunosuppressive agent, such as corticosteroids

A. Hemostatic agent, such as recombinant porcine sequence factor VIII B-domain-deleted product B. Hemostatic agent, such as recombinant factor VIIa C. Immunosuppressive agent, such as corticosteroids D. Immunosuppressive combination therapy, such as corticosteroids plus cyclophosphamide

A. 30 minutes B. 60 minutes C. 3 hours D. 8 hours

A. Development of inhibitor antibodies B. Infusion-related reactions C. Nausea/peptic ulcer disease D. Reactivation of viral infections

A. Allergic reactions occur in 1% of patients B. Thrombotic events occur in 5% of patients C. Thrombocytopenia occurs in 3% of patients D. No serious side effects have been reported